CSL Behring to Discontinue Mononine

CSL Behring is focused on delivering breakthrough therapies to improve  patients’ lives and meet the changing needs of our patients. Since CSL  Behring’s introduction of MONONINE® Coagulation Factor IX (Human) in 1992, advancements have been made for the treatment of Hemophilia B. Over time, patients have transitioned from older therapies to newer,  next generation treatment options, and very few patients currently remain on MONONINE in the US. Accordingly, we are discontinuing MONONINE.

CSL Behring is proactively notifying customers of this discontinuation to provide ample lead-time for Healthcare Professionals and MONONINE patients to select a new Factor IX treatment option. Based on current  supply, CSL Behring expects to have MONONINE available until at least  mid-2021.

We understand this news may be challenging for the patients who remain  on MONONINE. We encourage MONONINE patients to talk with their  Healthcare Professional soon to discuss alternate treatment options. In  addition, CSL Behring offers a medical information call center  1-800-504-5434, Monday–Friday 9AM to 5PM ET, for patients or Healthcare Professionals that have medical questions.